BACKGROUND: Genomic risk profiling involves the analysis of genetic variations linked through statistical associations to a range of disease states. There is considerable controversy as to how, and even whether, to incorporate these tests into routine medical care. OBJECTIVE: To assess physician attitudes and uptake of genomic risk profiling among an 'early adopter' practice group. DESIGN: We surveyed members of MDVIP, a national group of primary care physicians (PCPs), currently offering genomic risk profiling as part of their practice. POPULATION: All physicians in the MDVIP network (N =356) RESULTS: We obtained a 44% response rate. One third of respondents had ordered a test for themselves and 42% for a patient. The odds of having ordered personal testing were 10.51-fold higher for those who felt well-informed about genomic risk testing (p < 0.0001). Of those who had not ordered a test for themselves, 60% expressed concerns for patients regarding discrimination by life and longterm/disability insurers, 61% about test cost, and 62% about clinical utility. The odds of ordering testing for their patients was 8.29-fold higher among respondents who had ordered testing for themselves (p < 0.0001). Of those who had ordered testing for patients, concerns about insurance coverage (p = 0.014) and uncertain clinical utility (p = 0.034) were associated with a lower relative frequency of intention to order testing again in the future. CONCLUSIONS: Our findings demonstrate that respondent familiarity was a key predictor of physician ordering behavior and clinical utility was a primary concern for genomic risk profiling. Educational and interpretive support may enhance uptake of genomic risk profiling.
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BACKGROUND
Unlike most genetic testing for Mendelian disorders that produce a relatively certain prediction of disease, genomic profiling for common, complex diseases generates risk information. Genome profiling typically involves analyzing genetic variants (single nucleotide polymorphisms or SNPs) associated with diseases through statistical associations. Whole genome risk profiles are commercially available and may be ordered directly by consumers (DTC) from private companies. The relative genomic risk of most conditions included in these testing panels ranges from 1.04 to 3.2 1 ).
Disease prevention is predicted to be one of the major benefits of genomic or personalized medicine. Although interventions based on individual genomic risk could potentially lead to adoption of risk reduction behaviors, screening and/or early diagnosis and improved morbidity and mortality, the validity of genomic risk information and likelihood of improving health outcomes is unclear [2] [3] [4] .
Recent data cast doubt on the utility and/or added value of genetic testing [5] [6] [7] [8] [9] [10] [11] . Furthermore, many primary care physicians (PCPs) have limited knowledge of genetic testing or how to translate test results into clinically relevant information [12] [13] [14] [15] [16] .
Given their long-term relationship with patients and their families, PCPs are in a unique position to offer personalized medicine 17 . In order to gain insight into the pros and cons of incorporating genomic risk profiling into PCP practices, we conducted a survey of a physician group, MDVIP, which recently incorporated genetic testing into their practices. Specifically, we assessed physicians' familiarity with genomic risk testing, intended use of results, likelihood of future testing, perceived benefits and risks, and their preferences for education/training in genetic testing. In order to determine underlying factors that may influence physician attitudes, we also assessed familiarity and experience with genetic testing, as well as perceived adequacy of genetics training. We anticipate that these data will help identify factors that may facilitate as well as challenge the In December 2008, MDVIP and Navigenics announced a collaboration to integrate genomic-based preventive healthcare in physician offices. As part of this initiative, Navigenics offered complimentary genomic profiling to MDVIP physicians and discounted testing for MDVIP patients ($399; retail price was $999). The testing has not been used to market MDVIP services to patients. Testing is intended for patients interested in obtaining more information about their disease risk, those with an incomplete family history, and those interested in using genomic risk information to "personalize" preventive care. At the time, Navigenics' test analyzed SNPs associated with 28 conditions and diseases including obesity, heart attack, several cancers, dementia, and age-related macular degeneration. In 2009, pharmacogenetic testing was added to Navigenics' test. We did not distinguish between disease-risk and pharmacogenetic testing in this study. Testing is performed in a CLIA-certified lab on DNA extracted from a saliva sample.
Given physicians' limited knowledge of genetics and genetic testing [12] [13] [14] [15] [16] , prior to using the test physicians completed four online educational modules on genomic risk profiling developed by Navigenics. The modules provide an overview of the science underlying testing (genome-wide association studies), and the application of test results in preventive care 18 . In addition, Navigenics offers a free webinar overview of testing. Genetic counseling is a standard option offered to all Navigenics customers at no cost. Physicians were not encouraged to recommend the counseling service but to inform patients of its availability. Patient brochures were also made available, although it is unknown whether physicians distributed or displayed them.
Recruitment. The survey was administered January-March 2010. An advance letter from the MDVIP Medical Director informed physicians about the survey and encouraged participation. An invitation was then e-mailed to the PCPs with the survey URL. A follow-up fax invitation was sent to non-responders two weeks later. Participants were presumed to have consented if they initiated the survey by clicking "Next" on the first page, which provided information about the purpose, risks, and benefits of the study. All responses were anonymous; no compensation was provided.
Data Analysis. Analyses were performed using SAS and SAS/ STAT software (Version 9.2). Frequency counts and percentages were generated for each question. Write-in responses were either grouped into standing answer categories or placed into an "other" category. For tests of association between two categorical response variables, Fisher's exact tests were employed. Logistic and ordinal regression analyses were used to predict the likelihood of a particular response from a set of categorical and continuous covariates, including sex, time since medical school graduation, specialty, perceived adequacy of genetics training, perceived knowledge of traditional genetic testing and genomic risk testing, and use of traditional genetic testing. The effective sample size for analyses varied depending on the size of the subsample that completed the relevant section(s) of the survey.
RESULTS
Respondent Characteristics. A total of 171 physicians participated in the survey with 14 excluded due to incomplete data, yielding a 44% response rate. Respondents were predominantly male, white, and board-certified in internal medicine (Table 1) . Respondents were similar to the overall MDVIP population with respect to sex and medical specialty; and were more likely to be recent graduates, male, and to be internists as compared to U.S. PCPs.
Knowledge of Traditional Genetic Testing & Genomic Risk
Testing. Forty-five percent of respondents strongly or somewhat strongly agreed with the statement that they felt well-informed about genetic testing (defined as singlegene testing for disease susceptibility or diagnosis) and 52% strongly or somewhat strongly agreed with the statement that they would feel comfortable ordering genetic testing for disease susceptibility. However, 49% did not believe that their genetics training was adequate.
Of those who felt well-informed, 80% believed their training to be adequate. In contrast, of those who didn't feel wellinformed, 27% believed their training to be adequate. After adjusting for years since medical school graduation, sex, specialty, and frequency of ordering genetic testing in multiple logistic regression analysis, feeling well-informed about genetic testing lessened the odds of perceived The majority of respondents (90%) had heard of genomic risk profiling offered by companies such as Navigenics, 23andMe and deCodeMe. Of those, 42% strongly or somewhat strongly agreed that they felt well-informed about it. Each additional year since graduation was associated with an 11% reduction in the odds of having heard of genomic risk profiling, all else held constant (OR=0.89, p=0.015, CI=0.81 to 0.98). Of those who felt well informed about genomic risk profiling, 86% also felt well informed about traditional genetic testing. Holding years since graduation, sex, specialty, and frequency of ordering genetic testing constant, the odds of feeling wellinformed about genomic risk profiling were 13.67 times greater for those who felt well-informed about genetic testing compared with those who did not (p<0.001, CI=4.91 to 38.04), but 3.34 times lower for those who believed their training to be inadequate (p=0.02, CI=0.11 to 0.82).
Factors Impacting Use of Traditional Genetic Testing & Personal Genomic Risk Profiling. The majority of respondents reported ordering traditional genetic testing or referring to a genetics specialist 1-10 times/year (Table 2) . Of those who felt wellinformed, 76% ordered 1-10 genetic tests per year compared to 69% who did not feel well-informed (p=0.58). Holding years since graduation, sex, and specialty constant, the odds of ordering at least one genetic test per year were higher for those who felt well-informed about genetic testing (OR=3.77, p= 0.01, CI=1.30 to 10.87). There was a significant association between feeling well-informed about genetic testing and feeling "comfortable" ordering a genetic test for disease susceptibility, such that those who felt well-informed were more likely to feel comfortable (78.6%) than those who did not feel well-informed (29.8%; p < 0.0001).
Overall, 30% of respondents had ordered a genomic risk profile for themselves; 23% of those who had not yet ordered a test for themselves indicated that they intended to do so in the near future. Of those who felt well-informed about genomic risk testing, 59% ordered a genomic risk profile for themselves compared to 16% of those who did not feel well-informed (p< 0.0001). Holding years since graduation, sex, specialty, perception that genetics training was inadequate, and frequency of ordering traditional genetic testing constant, the odds of a respondent having ordered testing for him/herself were 10.5 times higher for those who felt well-informed about genomic risk profiling (Table 3) .
Forty-two percent of respondents indicated that they had ordered a genomic risk profile for a patient. Of those who had ordered a genomic risk profile for themselves, 77% also ordered a profile for a patient (OR=8.29, p<0.0001, CI=3.00 to 22.7). The odds of a respondent having ordered a genomic *Total percentages may add up to less than 100% as some respondents selected "Don't know/prefer not to respond" 94.2 n/a n/a African-American 0.6 n/a n/a Asian 3.8 n/a n/a Other/Prefer Not to Answer 2.5 n/a n/a Hispanic 1.9 n/a n/a Year Since Medical School Graduation 1-9 years 0 n/a 13. 4 10 risk profile for a patient were 4.6 times higher for those who felt well informed about genomic risk profiling (Table 3) . Moreover, compared with those who reported ordering 1-10 traditional genetic tests per year, respondents who never ordered traditional genetic tests were significantly less likely to have ordered a genomic risk profile for a patient. All else held constant; not having ordered for themselves likewise significantly reduced the probability of having ordered a genomic risk profile for a patient (Fig. 1) . Factors considered by respondents who ordered genomic risk profiling for their patients included patient request or interest (80%), clinical utility (68%), motivating adoption of preventive behaviors (68%), family history (64%), and the cost of testing (58%). Thirty of 46 respondents who had indicated patient request as a driver of ordering a profile had also ordered one for themselves. Respondents did not differ as to whether they did (35%) or did not (38%) intend to order genomic risk profiling for their patients in the next six months as part of an annual physical exam or personalized wellness plan. All else held constant, having ordered genomic risk profiling for patients was significantly associated with intention to order a profile for patients in the next six months (OR =2.82, p=0.03, CI=1.12 to 7.12). The odds of ordering a profile for patients in the future were 66% lower for internists than family medicine practitioners, the only significant difference noted between the two groups (Table 3) .
Concerns about Genomic Risk Profiling. When asked about
factors considered in their decision not to order a genomic risk profile for themselves, 53% expressed concerns about life and long-term/disability insurance discrimination, 50% about health insurance discrimination, 43% about confidentiality, 41% about inadequate knowledge of testing, and 36% indicated they did not believe testing would provide useful information.
There were no statistical differences between the top four of five concerns for patients between those who had ordered genomic risk profiling for their patients and those who did not. The top four concerns were uncertain clinical utility, risk of long-term/disability or life insurance discrimination, confidentiality, and cost of test (Table 4) . We assessed whether respondent characteristics were associated with the concerns of test cost, uncertain clinical utility, and potential for discrimination. The only association found was that respondents who ordered traditional genetic tests 11 or more times per year (vs. 1-3 times per year) were less likely to indicate concerns with cost (OR = 0.29, p =0.06, CI=0.08-1.03). Of 32 respondents who had not ordered a profile for themselves, almost all (94%) also expressed concern about clinical utility for patients. Similarly, of 48 respondents who had not Figure 1 . Predicted probability of ordering a genomic risk test for a patient compared to ordering frequency of traditional genetic tests.
ordered a genomic risk profile for themselves at least partially due to concern about life and long-term/ disability insurance discrimination, the majority (81%) also expressed concern about discrimination for patients; regardless, 29% had ordered genomic risk profiling for patients.
For respondents who had ordered a genomic risk profile for their patients, the following concerns were associated with a lower relative frequency of intention to order a profile in the next six months: insurance coverage (p = 0.014), uncertain clinical utility (p = 0.034), unfamiliarity with testing (p = 0.016), and communicating genomic risks (p = 0.040). If a respondent was unlikely to order a profile in the near future for a patient, the primary reason indicated was uncertain clinical utility (36%) followed by test cost (19%). Multiple concerns were compared between respondents who had already ordered genomic risk profiling for a patient and intended to order testing again in the near future (n =32) and those who had not already ordered genomic risk profiling for a patient and who did not intend to do so in the future (n = 62). Membership in the latter group was associated with relatively more frequent endorsement of concerns about insurance coverage (p=0.004), potential negative impact of testing (p =0.017), uncertain clinical validity (p =0.015) or clinical utility (p=0.025), unfamiliarity with testing (p<0.001), and communicating genomic risks (p=0.009). The relative frequency of concerns about long-term/disability or life insurance discrimination did not vary significantly across the two groups (p=0.37).
Preferred Educational Resources. Respondents most frequently endorsed continuing medical education (CME) as a means of learning about genetics in general (57% had used this type of resource), preferably through meetings and in-person courses, followed by journal publications (55%) and coursework in medical school (44%). Respondents preferred similar methods to learn about genomic risk profiling: CME courses (69%), medical journals (57%), professional medical meetings (53%), and educational programs offered by testing companies (47%). When asked about the best way to educate physicians about genomic risk profiling, respondents most frequently endorsed in-person CME (38%) followed by long-distance CME (10%), grand rounds and other in-house seminars (10%), and educational materials from testing laboratories (8%). All else held constant, we found insufficient evidence to conclude that years since graduation had an impact on feeling well-informed about genomic risk profiling for respondents who had not taken CME in genetics. However, for those who had taken CME in genetics, we found a lower probability of feeling wellinformed about genomic risk profiling in respondents with a greater number of years since graduation.
DISCUSSION
The field of genomics is moving at a remarkable pace, giving rise to commercial applications before their clinical validity and/or utility is clearly demonstrated, appropriate educational resources are developed, and potential benefits or harms are considered. Given that one of the anticipated benefits of genomic risk profiling is disease prevention, PCPs are a logical group to offer such testing to their patients and integrate the results with other types of risk assessments. This is the first study to assess initial uptake, interest, and concerns of genomic risk profiling among an early adoption group of PCPs. The results suggest that PCPs who feel well-informed about genomic risk testing are willing to include this type of information in a patient's risk assessment, even while acknowledging the uncertain clinical utility.
Although this is a relatively small group of physicians with a unique practice model, our findings indicate that their attitudes to traditional genetic testing are similar to those of nationally representative samples of PCPs 19, 20 . For example, a national study of PCPs reported that 60% have ordered a genetic test and 74% have referred a patient for genetic testing 19 compared to 82% and 62% in our study, respectively. In that survey, respondents who had received genetics training in medical school were almost twice as likely to have ever ordered a genetic test compared to those without such training (OR 1.80, 95% CI: 1.34 -2.43; p= 0.001). Several studies have reported limited physician knowledge of genetics, albeit higher in younger physicians and in disciplines more closely affiliated with genetics, namely pediatrics and obstetrics/gynecology 12, 15, 16 . Similarly, we found that time since graduation is linked to perceived inadequacy of genetics training, and perceived knowledge is linked to test ordering behaviors 21 .
Although actual use of genomic risk profiling has not been ascertained until now, physicians have expressed strong interest in predictive genetic testing for complex conditions 22, 23 . In just over a year since the partnership was established between Navigenics and MDVIP, about a third of respondents had ordered a test for themselves and ** Between-group difference in frequency of concern is significant at p<0.01 more than 40% had ordered tests for their patients. The heavily discounted cost of the test (free for physicians and 60% off retail for patients)) though, likely influenced the rate of uptake of the test. However, physicians' self-reported understanding of profiling was key given that those who accepted the offer of free testing were significantly more likely to report feeling well-informed about it.
Other studies have demonstrated that physicians' personal behavior influences practice behavior, with respect to exercise 24, 25 and preventive care 26 . We found that personal experience with the test was also an important factor related to test ordering for patients, perhaps as a result of increased physicians' familiarity with the test and comfort in ordering it for patients. These data also validate companies' strategies to partner with physicians to increase uptake of genomic risk profiling by providing the test at no cost to physicians along with free education. We did not ascertain if the availability of free access to a genetic counselor encouraged physicians to order a profile who did not feel well-informed or confident in their personal knowledge. We speculate that patient interest in profiling was also an important factor influencing physician behavior given that eight out of ten tests were ordered in response to patient requests. Patients' motivated to pay out-of-pocket to learn of their genetic predispositions may be more likely to adopt healthy lifestyles to reduce disease risk, potentially due to both interest and economic means to access healthy living initiatives 27 . However, these patients may also require more time to discuss the results to ensure understanding of the limitations of testing and other factors that may influence overall disease risk as well as any follow-up testing 28, 29 . In addition, it is unknown if these patients experience any undue stress or anxiety after learning of their genomic risks. Receipt of genetic disease risks has not been reported to cause long-term psychological harms 30, 31 , suggesting that individuals interested in learning about their genomic risks are better able or prepared to manage the information. Physician involvement may be critical to ameliorating concerns about test results as another study reported nearly half of individuals surveyed who had undergone DTC testing had concerns about the testing process/experience 33 . Although we were not able to assess characteristics of patients who underwent testing, prior studies have reported that individuals who are interested or have undergone genomic risk profiling tend to be White and have at least some college education [32] [33] [34] .
Low perceived clinical utility, as well as concerns about potential discrimination, have repeatedly been reported as primary barriers to uptake of both traditional genetic testing and newer applications [35] [36] [37] [38] [39] . Similarly, we found that uncertain clinical utility was among the top concerns of respondents for themselves and their patients. Interestingly, concerns about clinical utility did not significantly vary based on whether or not respondents had ordered a profile for a patient. Furthermore, we did not find that concerns of clinical utility was predictive of ordering behavior, unlike what was demonstrated for feeling wellinformed about genomic risk profiling or ordering of test for self. Although, there was a significant difference between internists and family physicians in the likelihood of ordering a genomic risk profile in the future, there were no other identifiable differences between the two groups. It is possible that training experiences are responsible for this difference, but further study will be necessary to discern the underlying factors. Graduate medical education requirements for family medicine include training in genetic counseling not required for internal medicine 40 . The rapid development of genomics over the last decade may quickly render physicians' education inadequate in this area, highlighting the need for CME courses, the preferred means of acquiring knowledge about genomic risk profiling. CME courses have been demonstrated to be an effective way to introduce new genetic tests and even increase personal interest [41] [42] [43] . We did not anticipate the inverse relationship observed between feeling well-informed about genomic risk testing and years since graduation in respondents who had taken CME in genetics. We speculate that respondents could be learning about new scientific findings or applications through CME courses and are more aware of what they did not learn about in medical school and therefore, reporting that they are not well-informed. Given the interest in genomic risk profiling demonstrated by our study, development of more educational opportunities will help enhance physicians' understanding and enable informed decision-making about the appropriateness of testing.
Although these data provide insight into physician use of genomic risk profiling, several limitations should be noted. Although the respondents were representative of the MDVIP network, their differences with the national PCP population limits the generalizability of the findings. The diversity of patients undergoing testing was likely limited given that patients had to pay for the test and the reported make-up of other users of genomic risk profiles 28, 32 . The heavily discounted cost of the test may have swayed physician and patient use of the test. In addition, the relationship with and education provided by Navigenics is unique to this group. However, these data are of significant interest as they provide an initial report on use of genomic risk profiling in a clinical setting. Future studies should focus on the impact including benefits and harms of genomic risk profiling, particularly in terms of physician and patient behavioral changes in patient management, treatment, and adoption of healthy behaviors.
